Niki Y, Hara H, Kawanishi M, Soejima R
Jpn J Antibiot. 1985 Sep;38(9):2526-31.
SM-4300, a newly developed human immunoglobulin for intravenous use, has been studied for the safety and effectiveness/efficacy in the 7 patients with severe respiratory infections and a patient with fever of undetermined origin. Severe infections in the patients considered of 3 cases of pneumonia, 2 of obstructive pneumonia due to lung cancer, 2 of diffuse panbronchiolitis and 1 of fever of undetermined origin. Clinical effects of SM-4300 were excellent in 1 case, good in 1, fair in 2 and poor in 4. The efficacy rate was 25.0%. The appearance of subjective and objective clinical side effects and abnormal laboratory findings related to SM-4300 administration were not noted.
SM - 4300是一种新研发的静脉用人免疫球蛋白，已在7例严重呼吸道感染患者和1例不明原因发热患者中对其安全性和有效性进行了研究。这些患者中的严重感染包括3例肺炎、2例肺癌所致阻塞性肺炎、2例弥漫性泛细支气管炎和1例不明原因发热。SM - 4300的临床效果为1例优、1例良、2例中、4例差。有效率为25.0%。未观察到与SM - 4300给药相关的主观和客观临床副作用及实验室检查异常结果。
